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Abstract 
 
Background 
Individuals of African ancestry in the US and Europe are at increased risk of developing 
schizophrenia and have poorer clinical outcomes. The antipsychotic clozapine, the only 
licensed medication for treatment-resistant schizophrenia, is under-prescribed and has 
high rates of discontinuation in individuals of African ancestry, due in part to increased 
rates of neutropenia. The genetic basis of lower neutrophil levels in those of African 
ancestry has not previously been investigated in the context of clozapine treatment. 
Methods 
We sought to identify risk alleles in the first genome-wide association study of 
neutrophil levels during clozapine treatment, in 552 individuals with treatment-resistant 
schizophrenia and robustly inferred African genetic ancestry. 
Results 
Two genome-wide significant loci were associated with low neutrophil counts during 
clozapine treatment. The most significantly associated locus was driven by rs2814778 
(β= -0.9, p=4.21x10-21), a known regulatory variant in the Atypical Chemokine Receptor 1 
(ACKR1) gene. Individuals homozygous for the C allele at rs2814778, known as the Duffy-
null genotype, were significantly more likely to develop neutropenia and have to stop 
clozapine treatment (OR=20.4, p=3.44x10-7).  
Conclusions 
Low neutrophil counts in individuals of African ancestry do not necessarily indicate an 
adverse drug reaction to clozapine, but can reflect benign ethnic neutropenia (BEN) due 
to the Duffy-null genotype. Thus, the rs2814778 genotype could be used as a 
pharmacogenetic test to revise safety-monitoring criteria for clozapine and address its 
under-prescription. This represents an important advance in personalised medicine in 
psychiatry with the potential to improve access to treatment for those of African 
ancestry with schizophrenia. 
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Introduction 
The incidence of psychotic disorders is increased in migrant populations1,2. In particular, 
individuals of African and African-Caribbean ethnicity in the UK and African American 
ethnicity in the US are at especially high risk of developing schizophrenia3,4. The exact 
causes of this are unknown, but are at least in part due to factors associated with being 
a member of a disadvantaged minority, such as socioeconomic stress and isolation5,6. 
Those of African and African-Caribbean ancestry have also been consistently 
demonstrated to have poorer clinical outcomes including higher rates of inpatient 
admissions involving the police or compulsion7,8. Furthermore, a recent study examining 
cases of first-episode psychosis in the UK found that in comparison with White British 
patients, Black African and Black African-Caribbean patients had a worse long-term 
clinical course with lower rates of recovery8.  
The antipsychotic clozapine is the only licenced treatment for those with schizophrenia 
who fail to respond to other antipsychotics (termed treatment-resistant 
schizophrenia)9,10. While clozapine has been robustly demonstrated to reduce the risk of 
rehospitalisation and to be associated with better symptomatic and functional 
outcomes11, it  is widely under-prescribed. Clozapine is particularly under-utilised in 
those of African American ethnicity in the US and Black African or African-Caribbean 
ethnicity in the UK12-16, populations that have also been consistently associated with a 
higher rate of clozapine discontinuation14,15,17-19. This is at least partly due to increased 
rates of neutropenia in those of African ancestry whilst taking clozapine19,20. 
Neutropenia is defined as an absolute neutrophil count less than 1500 cells/mm3, while 
agranulocytosis is diagnosed if the neutrophil count is below 500 cells/mm3 and is a 
severe condition that can endanger life. Clozapine treatment increases the cumulative 
risks of neutropenia (2.9%) and agranulocytosis (0.8%), which has led many countries to 
introduce regulatory systems for frequent blood monitoring whilst on the medication21. 
Recent evidence has indicated that genetics plays a role in susceptibility to neutropenia 
on clozapine. Genetic association studies have implicated HLA-DQB1 and HLA-B 
variants22,23, and rs149104283, a SNP intronic to transcripts of hepatic transporter genes 
SLCO1B3 and SLCO1B723 in individuals of European ancestry. Reflecting a general dearth 
of clinical and genetic research in non-European populations, all studies to date 
investigating clozapine-associated neutropenia have focused exclusively on individuals 
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of European ancestry, limiting the generalizability of findings. This is particularly relevant 
to those of African ancestry who are known to have lower baseline neutrophil counts on 
average compared to those from other populations24; this does not seem to impart an 
increased susceptibility to infection24 but nonetheless hampers clozapine initiation and 
treatment16,20.  
The presence of lower neutrophil counts in populations with African ancestry has a 
strong genetic component and has been robustly associated with the Duffy-null 
polymorphism rs2814778, an African-specific regulatory variant of Atypical Chemokine 
Receptor 1 (ACKR1/DARC)25-29. The impact of genetic variants associated with lower 
neutrophil counts, and in particular the Duffy-null genotype, has not been investigated 
in the context of clozapine treatment.  
In this study, we report the first GWAS of neutrophil levels during treatment with 
clozapine in individuals with treatment-resistant schizophrenia and robustly inferred 
African genetic ancestry.  
 
Methods 
Sample 
Individuals included in this study were from the CLOZUK2 sample, all of whom were 
prescribed clozapine in the UK with a clinician diagnosis of treatment-resistant 
schizophrenia. The samples were acquired anonymously in partnership with Leyden 
Delta (Nijmegen, Netherlands), a company that supplies and monitors clozapine in the 
UK, as part of the CRESTAR collaborative project (www.crestar-project.eu). The project 
has received UK National Research Ethics Service approval and was in accordance with 
the UK Human Tissue Act. All samples were anonymised and linked with blood 
monitoring data provided from clozapine blood monitoring databases. Full details of the 
CLOZUK2 sample are provided elsewhere30.  
Neutrophil data 
The neutrophil count for each individual was defined as the lowest absolute neutrophil 
count (ANC) on record during clozapine treatment within the blood monitoring database 
held by Leyden Delta, who retain all historical blood results within their monitoring 
system. It was not possible to obtain baseline neutrophil counts prior to clozapine 
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treatment. For clarity, the terms “ANC” and “neutrophil count” are used 
interchangeably. All results of ANC <1500 cells/mm3, indicating neutropenia and the 
standard threshold that triggers discontinuation of clozapine in the UK, were confirmed 
by either a) a consecutive ANC <1500 cells/mm3 or b) two or more results of ANC <2000 
cells/mm3 before or after the index result. We excluded individuals who in the opinion of 
their treating clinician had an alternative explanation for neutropenia such as 
concomitant immunosuppressive medication (n = 4).  
Genotype quality control and imputation 
The CLOZUK2 sample was genotyped by deCODE Genetics (Reykjavik, Iceland) on the 
Illumina HumanOmniExpress-12 chip. PLINK v1.931 was used for genotype quality control 
following standard protocols32. Maximum per-individual and per-marker missingness 
were set at 2%, and individuals with inbreeding coefficients (F) higher than 0.2 were 
removed from the dataset. After this curation process, 7,287 individuals genotyped at 
698,442 markers remained in the dataset. 
Genotype imputation was performed using the Haplotype Reference Consortium (HRC) 
panel and the pipeline offered by the Michigan Imputation Server33,34. As this pipeline 
allowed for imputation of autosomes only, genotype data from the X-chromosome were 
imputed on the Cardiff University RAVEN cluster35 using the SHAPEIT/IMPUTE2 
algorithms36 and a combination of the 1000 Genomes phase 3 (1KGPp3) and UK10K 
reference panels37. Both approaches to genotype imputation have been shown to 
produce compatible results and to perform similarly in terms of accuracy for variants 
with minor allele frequencies (MAF) larger than 1%33. After imputation, 20 million SNPs 
with INFO scores higher than 0.8 remained in the dataset. 
Defining Genetic Ancestry 
In order to select a cohort of individuals with African genetic ancestry, we stratified the 
CLOZUK2 individuals using Ancestry Informative Markers (AIMs), routinely employed in 
the field of forensic genetics38. The use of AIMs has been shown to be an efficient way of 
inferring biogeographical ancestry39,40, which reflects the genetic association of an 
individual to a particular continental or sub-continental population group. As these 
groups are broadly defined and show relatively large genetic differentiation41, this 
approach circumvents the problems associated with several other approximations to 
genetic ancestry42, such as self-reported ethnicity43 or country-of-origin44. Our analysis 
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of AIMs in the CLOZUK2 identified 566 individuals of Sub-Saharan African ancestry, of 
whom 552 had complete neutrophil count and covariate data, which we term CLOZUK2-
AFR. Details on the procedure used to select these individuals are provided in 
Supplementary Methods.  
Post-imputation curation of the CLOZUK-AFR genotype data 
From this sample, a total of 13.5 million SNPs were taken forward for analysis after 
applying a MAF filter of 1% and a Hardy-Weinberg Equilibrium (HWE) filter of p≤1x10-6. 
HWE tests were carried out using the exact “mid-p” test implemented in the 
“HardyWeinberg” R package45, as this test is valid for both autosomal and sex-linked 
markers. Relatedness was assessed using the PC-Relate approach, which identified 18 
pairs of relatives (?̂?≥0.2). For analyses sensitive to confounding by including related 
individuals, such as contingency table tests, we excluded one random member of each 
of these pairs. Otherwise, all individuals were included.  
Association analysis of neutrophil count 
Imputed data from the CLOZUK2-AFR individuals was analysed using the linear mixed 
model (LMM) implemented in GCTA v1.2646, specifically the “leave-one-chromosome-
out” procedure47. Genotype relatedness matrices, needed to control for population 
stratification and family structure in LMM frameworks, were calculated directly from the 
genotyped SNPs. Covariates used in the analyses included gender, age (at lowest ANC), 
age2 and total days on clozapine treatment. PLINK v1.948 was used to identify index SNPs 
in approximate linkage equilibrium (r2=0.1) using the LD-clumping procedure, with a p-
value cut-off of 10-4 and a distance cut-off of 3000 kb. Conditional analyses to further 
identify independent index SNPs were carried out using the GCTA-COJO procedure49. 
Imputation and analysis of human leukocyte antigen (HLA) alleles 
Previous research into clozapine-associated neutropenia has highlighted polymorphisms 
of the HLA system as drivers of adverse drug reactions in schizophrenia22,23,50. In order to 
investigate these, we imputed HLA classical alleles using the software HIBAG v1.1251 (see 
Supplementary Methods for further details). Association testing of the HLA classical 
alleles used linear regression of dosages weighted by imputation probabilities, following 
Levin et al. 201552. Covariates employed matched the GWAS described before, though 
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we added the first 5 principal components calculated by PC-AiR53 to correct for potential 
population stratification. 
 
Results 
Absolute neutrophil count in African individuals 
A GWAS of lowest ANC during treatment with clozapine in a total of 552 individuals of 
African ancestry (Figure 1; Supplementary Figure 1, λGC =0.985) identified six 
independent SNPs (r2<0.1) that were associated at the genome-wide significance level of 
p<5x10-8 (Table 1). Five of those SNPs were in close proximity at a locus (1q23.2) 
tagging, among others, ACKR1, previously called the Duffy Antigen Receptor Complex 
(DARC). The most significantly associated SNP in that locus was rs2814778 (β=-0.86, 
p=4.21x10-21), which is a regulatory variant in the ACKR1 promoter region. None of the 
other SNPs remained genome-wide significant after an analysis conditional on 
rs2814778, indicating this SNP is responsible for the association signal of the entire locus 
(Supplementary Figure 2). The other genome-wide significant signal was found on 
chromosome 9 (9q32), and its index SNP was rs77198048 (β =0.34, P =8.95x10-9), an 
intronic variant (MAF =1.07%) of the Zinc Finger Protein 618 (ZNF618) gene.  
rs2814778 genotype effect on neutrophil counts 
We examined the effects of the different rs2814778 genotypes on ANC after excluding 
18 related individuals who were included in the mixed model analysis, leaving 534 
CLOZUK2-AFR in the sample. Of these, 419 individuals were homozygous for the C 
(African) allele, 106 were heterozygous and 9 homozygous for the T (European) allele. A 
Mann-Whitney test (U=318, P=0.099) did not show significant ANC differences between 
CT and TT individuals, supporting previous evidence that the C allele has a recessive 
effect on neutrophil counts25. Thus, for all further analyses we combined individuals with 
TC and TT genotypes. Figure 2A displays the distribution of neutrophil counts during 
treatment with clozapine by rs2814778 genotype in our African ancestry sample. 
Individuals with the CC genotype had a median lowest ANC of 1900/mm3 compared to 
2900/mm3 for CT/TT individuals (U =9240, P =3.55x10-24).  
Figure 2B is a density plot showing the ANC distribution in different CLOZUK2 ancestry 
subsets (Supplementary Methods; Supplementary Table 5), stratified by rs2814778 
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genotype. While the difference between CC and CT/TT individuals is clearly shown, the 
CC neutrophil distributions are similar among Sub-Saharan Africans and North Africans 
(Kolmogorov-Smirnov test p-value=0.941). Similarly, the neutrophil distributions of 
CT/TT groups show no difference between Sub-Saharan Africans and all other ancestries 
(Kolmogorov-Smirnov test p-value=0.234, see Figure 2B).  
Given these results we then tested explicitly whether the rs2814778 Duffy-null genotype 
is more informative of ANC than genetic ancestry, using generalised linear modelling 
(Supplementary Methods). A model including genetic ancestry (European or African) 
and the GWAS covariates explained 8.29% of the variance in ANC. When the rs2814778 
genotype was added to this model, the variance explained increased to 10.94%, and 
genetic ancestry was no longer associated with ANC. The removal of genetic ancestry 
resulted in a statistically equivalent model (likelihood ratio test p-value=0.794) indicating 
that the rs2814778 genotype is more informative of ANC than genetic ancestry. 
A total of 83 (19.81%) CC individuals had neutropenia during treatment with clozapine 
(ANC < 1500/mm3) in comparison to 2 (1.74%) individuals with a T allele (Table 2). In 
both the US and UK, thresholds of ANC below which alterations in clozapine monitoring 
and management are indicated, have been defined based on normative values from 
European populations. In the UK, ANC results below 2000/mm3 mandate closer 
monitoring and more regular blood testing whereas ANC < 1500/mm3 requires clozapine 
treatment to be withdrawn. We used Barnard’s exact test to estimate the effect size of 
rs2814778 on crossing these thresholds, given their important clinical implications. CC 
individuals are much more likely to develop an ANC < 2000/mm3 (OR = 6.84, 95% CI = 
4.13-13.67, P = 2.90x10-16), and an ANC < 1500/mm3 (OR = 20.36, 95% CI = 5.37-314.28, 
P = 3.44x10-7) than T allele carriers. We could not test genotype-mediated differences at 
lower ANC thresholds, due to the absence of CT/TT carriers.  
rs2814778 and benign ethnic neutropenia 
There are regulatory mechanisms in place in the US and UK to lower the neutropenia 
threshold at which clozapine has to be discontinued for those deemed to have benign 
ethnic neutropenia (BEN), a hereditary condition characterised by mild, chronic 
neutropenia54-57. Of the 74 individuals in our sample with a formal diagnosis of BEN 
provided by a Consultant Haematologist, 72 (97.30%) have the CC genotype for 
rs2814778 (Table 2). Considering the safety and clinical outcomes of the 83 individuals 
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with a CC genotype and ANC <1500 cells/mm3, a total of 80 were rechallenged with 
clozapine. Of these, at the time of data collection 75 (93.75%) were still maintained on 
treatment, 4 (5.0%) had subsequently discontinued, and 1 had died (1.25%, unrelated to 
ANC).  
Association analysis of HLA alleles 
Using the HIBAG pipeline, we were able to impute 11 HLA-DQB1 classical alleles and 21 
HLA-B classical alleles at MAF > 1% in the CLOZUK2-AFR sample; none were significantly 
associated with ANC after Bonferroni correction for multiple testing (P < 0.05/32 = 
1.56x10-3), although the HLA-B*45:01 allele was nominally significant (P = 4.45x10-3).  
Assessment of previous findings from European populations 
We were unable to impute any of the following variants implicated in recent association 
studies of clozapine-associated neutropenia in European populations due to the risk 
alleles being absent or very rare in CLOZUK2-AFR; rs149104283 (intronic to transcripts of 
SLCO1B3 and SLCO1B7)23, the HLA-DQB1 candidate SNP rs11333249423, or the HLA-
DQB1 (126Q) and HLA-B (158T) amino acid polymorphisms22.  
 
Discussion 
In the first genetic association study of neutrophil counts during clozapine treatment in 
individuals of African ancestry, we identify two genome-wide significant loci. The most 
significant association is attributable to rs2814778 (P = 4.21x10-21), a regulatory variant 
in ACKR1 which has previously been associated with lower neutrophil counts in 
individuals of African ancestry, and is thought to be causal for BEN. We demonstrate 
that in those taking clozapine, individuals homozygous for the C allele for rs2814778, 
also known as the Duffy-null genotype, are substantially more likely (O.R. = 20.36) to be 
classified as having neutropenia (ANC < 1500 cells/mm3), the threshold at which 
clozapine must be withdrawn in the absence of BEN diagnosis. We further show that 
genotype at rs2814778 is a superior predictor of neutropenia than the current 
procedure for diagnosing BEN via haematological clinical assessment, and in doing so, 
suggest that genotyping at this locus may have clinical utility as a pharmacogenetic test. 
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The rs2814778 Duffy-null genotype is rare in most non-African populations58 but in 
those of African ancestry, it has been robustly implicated in white blood cell and 
neutrophil counts in several large meta-analyses25-28. It is also considered to be the 
cause of BEN55, an hereditary condition characterized by low neutrophil counts which 
occurs in 25-50% of individuals with African or Middle Eastern ancestry54-57. In support of 
rs2814778 as causal for BEN, over 97% of individuals diagnosed with BEN in our study 
were homozygous for the C allele. However, for those on clozapine, neither ancestry nor 
a clinical diagnosis of BEN was as good a predictor of low ANC as rs2814778 genotype. In 
contrast, the distribution of neutrophil counts closely followed genotype at rs2814778 
regardless of ancestry (African, European and South-West Asian) (Figure 2B). Given that 
rs2814778 is the likely cause of BEN and that the former performs better than the latter 
in predicting low ANC, this study implies that BEN is not adequately diagnosed in 
individuals treated with clozapine. Indeed this is demonstrated by our finding that only 
59% of those with the CC genotype and an ANC between 1000 and 1500 cells/mm3 had a 
clinical BEN diagnosis and were thus able to re-initiate clozapine. Indirect evidence also 
supports the hypothesis that BEN is under-diagnosed; BEN had a much lower frequency 
(14%) in our sample than expected from its prevalence of 25-50% in healthy populations 
of African ancestry54-57. Furthermore, the rates of BEN diagnosis in this sample will be 
overestimated given its cross-sectional nature (at the point of sample collection), which 
enriches for those that have been re-challenged with clozapine. Others have similarly 
noted under-representation of BEN in smaller samples of people of African ancestry 
taking clozapine16.  
The Duffy-null rs2814778 (C) allele disrupts an erythroid transcription factor GATA-1 
binding site in the promoter of ACKR1 and as a result, the erythrocytes of homozygote 
rs2814778 carriers do not express ACKR1 protein59. Recent experimental work in mice 
has shown that ACKR1 deficiencies during early haematopoiesis do not result in reduced 
production of neutrophils, rather neutrophils exhibit altered phenotypic characteristics 
that result in their preferential loss from blood by egress into tissues, particularly via 
migration to the spleen, thus causing neutropenia60. Importantly there is good evidence 
that BEN does not lead to increased rates of infection or clozapine-associated 
agranulocytosis19,20,61. In light of this, for patients with a diagnosis of BEN, clozapine 
monitoring thresholds in the UK are reduced to ANC > 1500 cells/mm3 and ANC < 1000 
cells/mm3 for initiation and discontinuation, respectively. The recently implemented 
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Clozapine Risk Evaluation and Mitigation Strategy (REMS) program in the US also 
allocates BEN patients separate monitoring thresholds of ANC > 1000 cells/mm3 for 
initiation and ANC < 500 cells/mm3 for discontinuation.  
Our study supports the safety of separate thresholds for those with BEN; 94% of 
rs2814778 C homozygotes with ANC < 1500 cells/mm3 were successfully maintained on 
clozapine treatment after reinstatement. However, in clinical practice, the process of 
diagnosing BEN is challenging, particularly for those who may be acutely psychotic at the 
point of clozapine initiation or as a result of clozapine withdrawal. In the UK and the US, 
a BEN diagnosis is made by a specialist in haematology after assessing the individual’s 
ancestral background, drug history, and the presence of stable low neutrophil counts in 
the absence of infection. All this necessitates referral by psychiatrists, attendance at 
haematology outpatient clinics, further blood sampling and review. In light of these 
practical considerations, it is perhaps unsurprising that only a minority of those who 
have treatment-resistant schizophrenia and who are eligible for a BEN diagnosis actually 
receive it, and then go on to have appropriate management with clozapine16.  
Our results indicate that genotyping rs2814778 offers a simple but sensitive alternative 
strategy for the diagnosis of BEN. In the context of clozapine treatment, individuals who 
are homozygous for the C allele and who do not show signs of compromised immune 
function could have revised neutrophil thresholds in line with current BEN monitoring 
procedures. This ability to prospectively lower acceptable neutrophil thresholds would 
address the underutilisation of clozapine in those of African ancestry in the US14,15 and 
UK16 by (i) enabling more of those suitable for clozapine to start the medication given a 
lower baseline threshold (ii) avoiding disruption of treatment for those who discontinue 
clozapine and may or may not under current arrangements be subsequently diagnosed 
with BEN. In addition to identifying BEN, rs2814778 could also avoid misclassification; 
the two individuals that had a BEN diagnosis but did not have the Duffy-null genotype in 
this study have likely been diagnosed incorrectly and could therefore be at increased risk 
of agranulocytosis. The potential applications extend beyond those of self-reported 
African ancestry given rs2814778 occurs at non trivial rates in other in which malaria has 
been historically endemic, including some parts of the Middle East, South West Asia and 
Oceania58.  
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It is important to note that the Duffy-null genotype is the main causal factor for the 
Duffy-null phenotype (classically termed “Fy(a-b-)”)58. Recent studies have shown that 
direct genotyping is the best available method to identify Duffy-null individuals in the 
context of neutropenia62,63, since in the isolated handful of reported cases with Duffy-
null phenotype in the absence of the rs2814778 mutation, neutropenia is not 
observed64. A further challenge to using Duffy-null phenotyping arises from other ACKR1 
mutations causing weak antigen expression which can mimic the Duffy-null phenotype 
causing serological ambiguity, resulting in misclassification of up to 3.5% of individuals 
depending on population62,65,66. For this reason, we argue that genotyping of rs2814778 
would outperform the serological typing of the Duffy-null phenotype. 
The second genome-wide significant finding corresponds to an intronic variant in the 
ZNF618 gene, which has been characterised recently as a contributor to methylation and 
chromatin binding of epigenetic regulators67. However, the associated locus on 
chromosome 9 contains a number of other genes and thus, based on the evidence from 
this study alone, a possible causal link with neutrophil counts or clozapine-associated 
effects cannot be inferred.  
In summary, we provide novel insights into the genetic architecture of neutrophil counts 
during clozapine treatment in individuals with African genetic ancestry. We demonstrate 
strong association with rs2814778, a regulatory variant in the ACKR1 gene that has also 
been described as the genetic basis for BEN. We suggest that rs2814778 genotyping 
offers an as yet rare opportunity for personalised medicine in psychiatry. Although we 
recognise further research is needed to establish the acceptability, uptake, clinical 
utility, and the practical outcomes and cost-benefits of such a test, rs2814778 
genotyping has the potential to assist decision making in the initiation and on-going 
management of clozapine treatment. Moreover the test presents an opportunity to 
increase uptake of clozapine in those of African ancestry, for whom access to the only 
effective medication for treatment-resistant schizophrenia is currently often denied. 
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Figure 1 
 
 
Manhattan plot of the lowest ANC GWAS in the CLOZUK2-AFR sample. The genome-
wide significant peak at chromosome 1 corresponds to the ACKR1 locus mentioned in 
the text. 
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Figure 2 
 
 
 
A: Histogram of lowest neutrophil count in the CLOZUK2-AFR sample, stratified by 
rs2814778 genotype. B: Scaled density plots of ANC in the different CLOZUK2 
biogeographical ancestry subsets, stratified by rs2814778 genotype. 
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Table 1 
 
Genome-wide significant SNPs from the ANC GWAS in the CLOZUK2-AFR sample. 
 
SNP CHR BP A1 A1 Frequency Beta s.e. P-value 
rs2814778 1 159174683 C 88.38% -0.856 0.091 4.21 x10-21 
rs4971072 1 155273869 G 92.25% -0.700 0.106 3.61 x10-11 
rs260913 1 163968414 C 4.45% 0.788 0.131 1.89 x10-9 
rs12128479 1 162268123 G 1.63% 1.205 0.203 2.98 x10-9 
rs77198048 9 116789254 T 1.07% 1.625 0.282 8.95 x10-9 
rs12143237 1 162480145 A 2.90% 0.877 0.153 1.11 x10-8 
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Table 2  
 
ANC and BEN diagnosis in CLOZUK2-AFR, stratified by rs2814778 genotype. 
 CC  TC/TT 
 N (% total CC) N BEN (%)  N (% total TC/TT) N BEN (%) 
ANC < 0.5 1 (0.24%) 1 (100.00%)  0 (0.00%) - 
0.5 ≥ ANC < 1 19 (4.53%) 14 (73.68%)  0 (0.00%) - 
1 ≥ ANC < 1.5 63 (15.04%) 37 (58.73%)  2 (1.74%) 1 (50.00%) 
1.5 ≥ ANC < 2 149 (35.56%) 17 (11.40%)  16 (13.91%) 0 (0.00%) 
ANC ≥ 2  187 (44.63%) 3 (1.60%)  97 (84.35%) 1 (1.03%) 
Total 419 (100.00%) 72 (17.18%)  115 (100.00%) 2 (1.73%) 
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